New UK trial aimed at revolutionising prostate cancer screening begins

• The landmark Transform trial has commenced in the UK, testing its first male participants for prostate cancer screening.
• Funded by Prostate Cancer UK and the National Institute for Health and Care Research (NIHR), the trial seeks to identify the most effective combination of tests, such as genetic analysis or rapid MRI scans, for future population-wide screening programmes.
• This development coincides with the UK National Screening Committee (UKNSC) advising against population-wide PSA testing, citing potential harm, and recommending screening only for men with BRCA1 and BRCA2 genetic mutations.
• Experts hope the Transform trial will yield significant results within two years, with the UKNSC agreeing to review new evidence that could prompt changes to current screening practices.
• The trial aims to gather crucial data, particularly for Black men who face double the risk of prostate cancer, with a target of 10% Black participants to ensure meaningful representation.

IN FULL

Landmark UK prostate cancer screening trial begins with first men tested